However, compared with the unprecedented success of PD-L1 combined with EP in the first-line treatment of ES-SCLC patients, programmed cell death 1 (PD-1) inhibitors showed unsatisfactory efficacy outcomes. Here, PDCD1 is linked to small cell lung carcinoma.